EquityZen Growth Technology Fund II LLC - Series 30
Raised
$4M
Investors
4
Min Invest
$179,805
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund II LLC - Series 30 is a Delaware-organized pooled investment fund filed by EquityZen Advisors LLC and Phil Haslett on September 29, 2025. The entity raised $4.2M from 4 investors under Rule 506(b) and 3(c) exemptions, with a minimum investment of $180K. This Series vehicle is part of the EquityZen platform, which operates approximately 150 related EDGAR entities focused on private equity secondaries.
This offering follows the standard 506(b) private placement pattern typical of private equity fund vehicles, with a $180K minimum investment positioning it in the mid-tier accredited investor segment. The exemption structure and series-based fund architecture align with conventional SPV operations in the secondary private equity market.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, X1
Phil Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. AltStreet analysis (summaries, flags, category context) is generated by Claude from this primary source data and reviewed for accuracy. Platform-provided information (if present) is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. EDGAR data is verified read-only — platforms may request factual corrections for demonstrable inaccuracies by contacting research@altstreet.investments. This page does not constitute investment advice.
